{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:22:37Z","timestamp":1775020957519,"version":"3.50.1"},"reference-count":39,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"The Psychiatric Research Unit, Region Zealand Psychiatry","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Mental Health Services of Region Zealand Psychiatry East","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Psychiatric Centre Glostrup, Unit for Complicated Schizophrenia","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,30]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to investigate the perspectives of clozapine-na\u00efve outpatients with treatment-resistant schizophrenia on clozapine commencement and the barriers and facilitators of it.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A mixed-methods convergent design was employed using both qualitative and quantitative data on the same items.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>In-home visits or meetings at three Mental Health outpatient facilities in Region Zealand East, Denmark.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Clozapine-eligible, yet clozapine-na\u00efve, outpatients with schizophrenia. A convenience sample of 206 patients with schizophrenia treated with antipsychotic polypharmacy (APP) was screened for clozapine eligibility. Clozapine eligibility included recurrent\/continued prescription of APP throughout the past year, \u2265 3 different antipsychotics (APs) trialled at a therapeutic dose and \u22652 APs trialled adequately before current treatment. All eligible patients able to provide written informed consent were invited to participate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The participants\u2019 perspectives were assessed qualitatively through semistructured interviews and quantitatively with closed-ended questions, numerical scale ratings, and standardised patient-reported outcome measures. Moreover, the participants\u2019 sociodemographic and clinical characteristics were collected through case files, participant questionnaires, and clinical ratings made by the participants\u2019 treating clinicians. Interviews were transcribed verbatim and analysed thematically. Quantitative data were analysed with descriptive statistics. Finally, qualitative and quantitative results were compared and merged to draw meta-inferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen patients were included, 10 (56%) were men and the median age was 30.0 years (IQR 24.8\u201337.8). Nine participants (50%) were willing to commence clozapine if offered now, nine were not. No apparent clinical or socioeconomic differences were observed between refusers and acceptors; however, the acceptors rated their subjective recovery on the Brief INSPIRE-O significantly lower than the refusers did, and qualitatively, they all expressed subjective distress due to their current symptoms. Three themes characterised the refusers\u2019 reasons for not accepting clozapine: \u2018Reconciliation with the current situation warrants no change in treatment\u2019, \u2018Clozapine is a last-resort treatment for last-resort people\u2019 and \u2018Permanent or situational reluctance due to practical aspects of treatment\u2019. In the vast majority of cases, blood sampling had little or no impact on the participants\u2019 current willingness to commence clozapine, and quantitatively, blood sampling ranked lowest of the suggested barriers, whereas hospital admission for clozapine commencement ranked highest. The adverse side effects of clozapine, sedation and, weight gain in particular, were considered a major barrier if previously encountered with ineffective AP trials. The introduction of individualised commencement plans mitigating personal barriers was highlighted as the facilitator with the greatest impact on clozapine willingness, able to turn refusals into acceptance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Patients tend to prefer the predictability in status quo over switching to clozapine if they previously have trialled multiple APs with inadequate symptom reduction and subsequent deterioration\/rehospitalisation or AP-induced weight gain and sedation. Moreover, the impression that clozapine treatment was unmanageable or a last-resort option further accentuated their reluctance to switch. Antipsychotic-trial fatigue and the stigma of clozapine as a last-resort treatment should be avoided by adhering to guidelines, thereby limiting the number of antipsychotics trialled before offering clozapine. Fortunately, it seems as if the patient\u2019s willingness to trial clozapine is positively impressionable to the conversation about customised commencement plans offering commencement on the patient\u2019s terms. For patients with subjective distress due to their symptoms, such plans can even reverse an initial clozapine refusal\n                      <jats:named-content content-type=\"\">Cite Now<\/jats:named-content>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-093394","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T04:57:08Z","timestamp":1742533028000},"page":"e093394","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Perspectives of clozapine-na\u00efve outpatients with treatment-resistant schizophrenia on clozapine commencement: a mixed-methods convergent study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-9074","authenticated-orcid":false,"given":"Michelle Iris","family":"Jakobsen","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen, Denmark"},{"name":"Psychiatric Services Region Zealand East, Roskilde, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen F","family":"Austin","sequence":"additional","affiliation":[{"name":"Psychiatric Services Region Zealand East, Roskilde, Denmark"},{"name":"Department of Psychology, University of Copenhagen, Faculty of Social Sciences, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0204-7745","authenticated-orcid":false,"given":"Ole Jakob","family":"Storeb\u00f8","sequence":"additional","affiliation":[{"name":"Psychiatric Research Unit, Psychiatric Services Region Zealand, Slagelse, Denmark"},{"name":"Department of Psychology, University of Southern Denmark, Faculty of Health Sciences, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6134-2392","authenticated-orcid":false,"given":"Erik","family":"Simonsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen, Denmark"},{"name":"Psychiatric Services Region Zealand East, Roskilde, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimmi","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen, Denmark"},{"name":"Psychiatric Centre Glostrup, Unit for Complicated Schizophrenia, Mental Health Services of the Capital Region of Denmark, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"2025121514073543000_15.3.e093394.1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0311-1"},{"key":"2025121514073543000_15.3.e093394.2","first-page":"51","article-title":"Rediscovering clozapine: clinically relevant off-label uses","volume":"15","author":"Newman","year":"2016","journal-title":"Curr Psychiatr"},{"key":"2025121514073543000_15.3.e093394.3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/acps.13111","article-title":"How and when to use clozapine","volume":"141","author":"Rubio","year":"2020","journal-title":"Acta Psychiatr Scand"},{"key":"2025121514073543000_15.3.e093394.4","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050503"},{"key":"2025121514073543000_15.3.e093394.5","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0000000000000478"},{"key":"2025121514073543000_15.3.e093394.6","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12742"},{"key":"2025121514073543000_15.3.e093394.7","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1177\/0269881119855995","article-title":"Prevalence of treatment-resistant psychoses in the community: A naturalistic study","volume":"33","author":"Beck","year":"2019","journal-title":"J Psychopharmacol"},{"key":"2025121514073543000_15.3.e093394.8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/08039488.2022.2160878","article-title":"Antipsychotic prescribing practices for outpatients with schizophrenia and reasons for non-clozapine treatment - Data from a Danish quality assessment audit","volume":"77","author":"Jakobsen","year":"2023","journal-title":"Nord J Psychiatry"},{"key":"2025121514073543000_15.3.e093394.9","doi-asserted-by":"publisher","DOI":"10.3371\/CSRP.4.1.4"},{"key":"2025121514073543000_15.3.e093394.10","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2215-0366(24)00314-6","article-title":"Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis","volume":"11","author":"H\u00f8jlund","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"2025121514073543000_15.3.e093394.11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1192\/bjb.2018.67","article-title":"Barriers to using clozapine in treatment-resistant schizophrenia: systematic review","volume":"43","author":"Farooq","year":"2019","journal-title":"BJPsych Bull"},{"key":"2025121514073543000_15.3.e093394.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-085956","article-title":"What is the current scope of research assessing patients\u2019 and clinicians\u2019 perspectives on clozapine treatment? A comprehensive scoping review","volume":"15","author":"Jakobsen","year":"2025","journal-title":"BMJ Open"},{"key":"2025121514073543000_15.3.e093394.13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/YIC.0000000000000188","article-title":"Patient attitudes to clozapine initiation","volume":"32","author":"Gee","year":"2017","journal-title":"Int Clin Psychopharmacol"},{"key":"2025121514073543000_15.3.e093394.14","unstructured":"Creswell JW . A concise introduction to mixed methods research. SAGE Publications, 2021."},{"key":"2025121514073543000_15.3.e093394.15","doi-asserted-by":"crossref","unstructured":"Morse JM . Mixed method design: principles and procedures. Taylor & Francis, 2016.","DOI":"10.4324\/9781315424538"},{"key":"2025121514073543000_15.3.e093394.16","unstructured":"Creswell JW , Clark VLP . Designing and conducting mixed methods research. California: Sage Publications 2007:64,"},{"key":"2025121514073543000_15.3.e093394.17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.34190\/ecrm.23.1.2444","article-title":"Pragmatism as a Research Paradigm","volume":"23","author":"Elgeddawy","year":"2024","journal-title":"Ecrm"},{"key":"2025121514073543000_15.3.e093394.18","doi-asserted-by":"publisher","DOI":"10.1258\/jhsrp.2007.007074"},{"key":"2025121514073543000_15.3.e093394.19","doi-asserted-by":"publisher","DOI":"10.1097\/ACM.0000000000000388"},{"key":"2025121514073543000_15.3.e093394.20","unstructured":"Bech P . Measuring the dimension of psychological general well-being by the WHO-5. Quality of Life Newsletter 2004;15\u20136."},{"key":"2025121514073543000_15.3.e093394.21","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1327020","article-title":"Scalability, test-retest reliability and validity of the Brief INSPIRE-O measure of personal recovery in psychiatric services","volume":"15","author":"Moeller","year":"2024","journal-title":"Front Psychiatry"},{"key":"2025121514073543000_15.3.e093394.22","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700050182"},{"key":"2025121514073543000_15.3.e093394.23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11 Suppl 3","author":"Sheehan","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"2025121514073543000_15.3.e093394.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(03)00189-0"},{"key":"2025121514073543000_15.3.e093394.25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cbm.313","article-title":"Reasons for non\u2010prescription of clozapine in treatment\u2010resistant schizophrenia","volume":"9","author":"Swinton","year":"1999","journal-title":"Criminal Behav Ment Health"},{"key":"2025121514073543000_15.3.e093394.26","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"2025121514073543000_15.3.e093394.27","unstructured":"Microsoft Excel [program] (16.0) version, 2018. 2019."},{"key":"2025121514073543000_15.3.e093394.28","unstructured":"R: A language and environment for statistical computing. [program]. R.4.2.1. version. Vienna, Austria. R Foundation for Statistical Computing. 2022."},{"key":"2025121514073543000_15.3.e093394.29","unstructured":"RStudio: Integrated Development for R [program]. Boston, MA: RStudio. 2022."},{"key":"2025121514073543000_15.3.e093394.30","unstructured":"NVivo qualitative data analysis. Version 12 [software] [program]. 12 version: QSR International Pty Ltd. 2018."},{"key":"2025121514073543000_15.3.e093394.31","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"2025121514073543000_15.3.e093394.32","unstructured":"Jakobsen MI , Austin S , Simonsen E , et al . Individual quantitative data. OSF, 2024."},{"key":"2025121514073543000_15.3.e093394.33","doi-asserted-by":"crossref","DOI":"10.1038\/s41537-023-00423-3","article-title":"Non-prescribing of clozapine for outpatients with schizophrenia in real-world settings: The clinicians\u2019 perspectives","volume":"9","author":"Jakobsen","year":"2023","journal-title":"Schizophrenia (Heidelb)"},{"key":"2025121514073543000_15.3.e093394.34","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13522"},{"key":"2025121514073543000_15.3.e093394.35","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231165169","article-title":"Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series","volume":"13","author":"Prasad","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"2025121514073543000_15.3.e093394.36","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/acps.13734","article-title":"Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: A systematic review and meta-analysis","volume":"150","author":"Bak","year":"2024","journal-title":"Acta Psychiatr Scand"},{"key":"2025121514073543000_15.3.e093394.37","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2023.532","article-title":"Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST)","volume":"9","author":"Siskind","year":"2023","journal-title":"BJPsych open"},{"key":"2025121514073543000_15.3.e093394.38","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1017\/S0033291721000246","article-title":"Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis","volume":"51","author":"Griffiths","year":"2021","journal-title":"Psychol Med"},{"key":"2025121514073543000_15.3.e093394.39","unstructured":"Jakobsen MI , Austin S , Storeb\u00f8 OJ , et al . Patients\u2019 and clinicians\u2019 attitudes towards clozapine treatment [PhD project], 2021. Available: https:\/\/doi.org\/10.17605\/OSF.IO\/EXRGC"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-093394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:07:45Z","timestamp":1765836465000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-093394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,18]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/bmjopen-2024-093394"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-093394","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}